The price of focus: Cognitive doping and its hidden neuropsychiatric costs

Introduction

The non-medical use of methylphenidate among university students has emerged as a significant and escalating phenomenon, particularly within highly competitive academic settings such as medical schools. Frequently conceptualized as “cognitive enhancement” or “pharmacological neuroenhancement,” this behavior reflects both intensifying academic demands and a broader sociocultural emphasis on performance optimization. Despite its perceived efficacy in augmenting attention, vigilance and productivity, growing evidence raises critical concerns regarding its true cognitive benefits, safety profile and neuroethical implications.

Objectives

This review aims to critically appraise the current literature on non-prescribed methylphenidate use among medical students, with particular emphasis on cognitive outcomes, patterns of misuse, and potential long-term neuropsychiatric and cardiovascular risks.

Methods

A comprehensive literature search was conducted using PubMed, UpToDate and ClinicalKey databases. Peer-reviewed original studies, systematic reviews and meta-analyses were selected following rigorous critical appraisal. Priority was given to studies examining neurocognitive performance, underlying neurobiological mechanisms, and longitudinal safety outcomes, ensuring both clinical relevance and translational applicability.

Results

Non-medical use of prescription stimulants is prevalent among university populations, with lifetime prevalence estimates ranging from 5.3% to 35%. Medical students appear particularly susceptible, with reported misuse rates of approximately 5.8% in some cohorts and up to 16% in others. European data further indicate usage rates of 5% among undergraduates and 14% among candidates preparing for high-stakes licensing examinations. Primary motivations include enhancement of sustained attention, prolongation of study duration, mitigation of fatigue and perceived academic advantage. However, evidence supporting genuine cognitive enhancement in healthy individuals remains equivocal. Meta-analytic findings suggest modest improvements in working memory and processing speed, with inconsistent effects on attention and vigilance. Notably, benefits are minimal or absent in higher-order domains such as executive functioning, cognitive flexibility, and creative problem-solving. Furthermore, subjective perceptions of improved performance frequently exceed objective cognitive gains, suggesting that methylphenidate may preferentially modulate arousal, motivation and self-efficacy rather than core cognitive capacity. From a neurobiological perspective, methylphenidate exerts its effects through inhibition of dopamine and norepinephrine transporters, enhancing catecholaminergic transmission in prefrontal and mesolimbic circuits. While therapeutically beneficial in attention-deficit/hyperactivity disorder, such modulation in healthy individuals may dysregulate reward processing, reinforcement learning, and motivational salience, potentially increasing vulnerability to maladaptive behavioral patterns. Safety concerns are clinically significant. Acute adverse effects include insomnia, anxiety, irritability, appetite suppression, tachycardia and hypertension. Regulatory authorities highlight its high abuse liability and risk of substance use disorder. Epidemiological data suggest a modest but notable increase in cardiovascular events following initiation, with prolonged exposure associated with elevated risks of hypertension and arterial disease.

Conclusions

Non-medical methylphenidate use among medical students constitutes a multifaceted issue at the intersection of psychiatry, neuroscience and ethics. Its purported cognitive benefits lack robust empirical support, whereas potential neuropsychiatric and cardiovascular risks warrant concern. Addressing this phenomenon requires targeted psychoeducational interventions, enhanced regulatory oversight, and the promotion of sustainable, evidence-based strategies for cognitive optimization. Crucially, longitudinal research is needed to elucidate long-term outcomes and inform clinical and public health policy.

References

oFaraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353-64.; oSmith ME, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717-741; oMaier LJ, Ferris JA, Winstock AR. Pharmacological cognitive enhancement among non-ADHD individuals-A cross-sectional study in 15 countries. Int J Drug Policy. 2018 Aug;58:104-112. ; oAdvokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev. 2010;34(8):1256-1266; oRepantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res. 2010 Sep;62(3):187-206; oUrban KR, Gao WJ. Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain. Front Syst Neurosci. 2014 May 13;8:38.; oLakhan SE, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav. 2012 Sep;2(5):661-77.; oClemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014 Sep;126(5):64-81; oMiranda M, Barbosa M, Ferreira C, Silva M. Use of cognitive enhancers by Portuguese medical students. Acta Med Port. 2022;35(4):257–263. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14220; oCavaco AM, Ribeiro J, Nørgaard LS. Exploring cognitive enhancement substance use among Portuguese university students. Explor Res Clin Soc Pharm. 2022;5:100097. Availablefrom:https://www.sciencedirect.com/science/article/pii/S2667276621000974; oMiranda M. Use of cognitive enhancers by Portuguese medical students [dissertation]. Lisbon: Universidade Nova de Lisboa; 2020. Available from: https://comum.rcaap.pt/bitstream/10400.26/46477/1/Use%20of%20Cognitive%20Enhancers%20by%20Portuguese%20Medical%20Students-.pdf; oSmith ME, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717–741; oVolkow ND, Wang GJ, Fowler JS, Telang F. Imaging dopamine’s role in drug abuse and addiction. JAMA. 2009;301(11):1148–1150; oWilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Clin Psychiatry. 2008;69(12):1875–1884; oZhang L, Pan Y, Li X, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(3):242–251.